3-Thienyl/benzothienylchromones. Synthesis and properties by Gorbulenko, Natalia et al.
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2020, VOLUME 08, ISSUE 01)  
 
174 
 
3-Thienyl/benzothienylchromones. Synthesis and properties 
Natalia V. Gorbulenko*, Tatiana V. Shokol, Vladimir P. Khilya  
Department of Chemistry, Taras Shevchenko National University of Kyiv, 
Volodymyrska Street, 64/13, Kyiv 01601, Ukraine 
n gorbulenko@ukr. net 
 
Keywords: 3-hetarylchromones, α-hetaryl-2-hydroxyacetophenones, chromones, thiophene and 
benzothiophene compounds, cyclization reactions, coupling reactions. 
This mini-review for the first time summarizes and systematizes all the data available in the 
literature on the synthesis and properties of 3-thienyl/benzothienylchromones, starting from 1960. 
Two main approaches to the formation of target structures are presented. The conditions of 
cyclization reactions, oxidative rearrangement, transition metals catalyzed CH activation and 
annulation reactions, etc. are discussed. Testing data for some types of biological activity of a 
number of the 3-thienyl/benzothienylchromones and the products of their transformation into the 
pyrazole cycle are given.  
________________________________________________________________________________ 
Introduction 
       One of the most promising ways to create 
new biologically active compounds for medical 
chemistry is certainly the synthesis of analogues 
of natural low molecular weight bioregulators. 
A synthetically realized combination of natural 
benzopyrone structures, such as “drug-like 
natural matrices”, with pharmacophores such as 
S-, O-, N-containing heterocycles, which are 
structural elements of many not only synthetic, 
but also endogenous biologically active 
compounds, has led to fundamentally new 
structures - the so-called “double drugs”, a 
potential bispharmacophore drugs.  
       Modification of isoflavonoids by replacing 
the aryl substituent with a heterocyclic 
substituent in the classical isoflavone structure 
was first successfully implemented in 1960 [1]. 
The described thienyl analogues of estrogenic 
isoflavones turned out to be the first 
representatives of 3-hetarylchromones and 
stimulated the further development of synthesis 
methods and the study of the properties of this 
fundamentally new type of compounds. Against 
the background of a consistently high number of 
scientific and patent publications, review 
articles on 3-hetarylchromones with N- and O-
containing heterocycles, there are relatively few 
materials on 3-hetarylchromones with S-
containing heterocycles, mostly published after 
2000 and, as far as is known, were not 
systematized. 
       To a certain extent, the observed increase in 
the publication activity of 3-hetarylchromones 
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with S-containing heterocycles is associated 
with the increased use of cross-coupling 
reactions for the preparation of heterocyclic 
compounds of various structures over the past 
two decades [2]. Among all these reactions 
catalyzed by transition metals, the Suzuki-
Miyaura reaction, which uses boronic acids or 
esters, remains the method of choice. Advances 
in the synthesis and study of the reactivity of 
new heterocyclic boronic acids make it possible 
to create target libraries that are now mandatory 
in medical chemistry [3]. 
       This review summarizes the results of 
research for the synthesis and biological 
screening of 3-thienyl/benzothienylchromones. 
Two main approaches used in the synthesis of 
target 3-hetarylchromones, such as cyclization 
of S-containing ring synthons into chromone 
system or introduction of an S-containing 
heterocycle to the chromone system are 
highlighted. Chemical properties were 
represented only by a single example of a 
reaction with hydrazine hydrate. The range of 
biological action of the target 3-
hetarylchromones and some their transformation 
products into the pyrazole cycle was 
determined. 
 
1. Synthesis of 3-thienylchromones by the 
formation of the pyrone cycle from synthons, 
including S-containing heterocycle   
 
The first synthesized heteroanalogs of 
isoflavones were thienyl derivatives 1–3 
obtained upon cyclization of α-(2-thienyl)-2,4,6-
trihydroxyacetophenone 4 with ethyl oxalyl 
chloride and subsequent transformations of 2-
ethoxycarbonyl-3-(2-thienyl)-5,7-
dihydroxychromone 1 on the ethoxycarbonyl 
group (hydrolysis and decarboxylation) [1] 
(Scheme 1).  
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Scheme 1. The synthesis of 2-(un)substituted-3-(2-
thienyl)-5,7-dihydroxychromones  
 
       The patent [4] discloses the synthesis of 5- 
(7-hydroxy-4-oxo-2-trifluoromethyl-4H-
chromen-3-yl)thiophen-2- and thiophene-3-
carboxylic acids 5, 6 and their methyl esters 7, 8 
by cyclization of the corresponding α-(2-
thienyl)-2,4-dihydroxyacetophenones 9, 10 with 
trifluoroacetic acid in the presence of 
triethylamine in dichloromethane at 0 °C 
(Scheme 2). 
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Scheme 2. The synthesis of 5-(7-hydroxy-4-oxo-2-
trifluoromethyl)-4H-chromen-3-yl)thiophen-2- and 
thiophene-3-carboxylic acids and their methyl esters 
 
       The thienyl derivatives of benzodipyranone 
of an asymmetric and symmetrical structure - 
benzodipyrano-4,10-dione 11 and 
benzodipyrano-4,6-dione 12 were obtained by 
the Vilsmeier-Haack reaction from the 
condensation product of phloroglucinol and 2-
thienylacetonitrile 13 with methanesulfonyl 
chloride and N, N-dimethylformamide in boron 
trifluoride etherate at 120 °C [5] (Scheme 
3).
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Scheme 3. The synthesis of thienyl derivatives of 
benzodipyrano-4,10-dione and benzodipyrano-4,6-dione  
       The work [6] described examples of the 
oxidative rearrangement of a 2′-hydrochalcone 
with various substituents (R) in ring B using 
1H-1-hydroxy-5-methyl-1,2,3-benzodioxathiol 
3,3-dioxide (HMBI). Direct conversion took 
place by boiling in methanol, without the need 
for preliminary protection of the 2’-hydroxy 
group of the chalcone. Derivatives of terminal 
isoflavones are formed as the main product, and 
2,3-dihydro-2-R-3-benzofurancarboxylic acid 
methyl esters and the corresponding flavone 
derivatives are formed in low yields. In the case 
of a 2'-hydroxychalcone with a thienyl 
substituent in ring B 14, 3-(2-thienyl) chromone 
15 was obtained in 34% yield, and the yields of 
2,3-dihydro-2-(2-thienyl)-3-
benzofurancarboxylic acid methyl ester 16 and 
2-(2-thienyl)chromone 17 were determined to 
be 6% and 0%, respectively, based on 1H NMR 
spectroscopy data, using the internal standard in 
a separate experiment (Scheme 4). 
 
OH
O
S
O
O
SO
O
S
OMe
O
O
S
14
17  (0%)*16  (6%)*15  (34%)
 HMBI (2 equiv)
MeOH,
+ +
 24 h
 
 
Scheme 4. The synthesis of  3-(2-thienyl)chromone  
        
       The catalyzed by transition metals reactions 
of CH-activation and annulation are an effective 
tool for the synthesis of 3-hetarylchromone 
derivatives. The role of the catalyst/catalytic 
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complex is not only to accelerate the speed of 
the process, but can also affect the selectivity of 
the chemical reaction.  
       In the coupling reaction of 1-(2-tert-
butyldimethylsilyloxy)phenyl-3-phenyl-2-
propyn-1-one 18 with 2-iodothiophene in 
absolute methanol in the presence of catalytic 
amounts of Pd(PPh3)4 and CuI and K2CO3 as 
base 2-(1-thienyl-1-phenylmethylene) 
benzofuranone 19 and 2-phenyl-3-
thienylchromone 20 were obtained [7] (Scheme 
5). 
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Scheme 5. The synthesis of 2-phenyl-3-(2-
thienyl)chromone 
      
A new effective method for the synthesis of 3-
substituted 2-aminochromones promoted by    
Sn(IV) annulation of ynamides with 2-methoxy 
aroyl chlorides under mild conditions was used 
to obtain 3-(2-thienyl)chromone having 
substituted аmino group at C-2 21. This method 
provides concomitant construction of C-C and 
C-O bonds between ynamides and 2-methoxy 
aroyl chlorides according to the tandem Friedel-
Crafts acylation/Michael addition/ elimination 
strategy [8] (Scheme 6). 
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Scheme 6. The synthesis of 3-(2-thienyl)chromone 
having substituted аmino group at C-2 
 
By direct oxidative coupling of salicylic 
aldehyde 22 with bis(2-thienyl)acetylene 23 in 
the presence of a rhodium catalyst, 
cyclopentadiene ligand and copper(II) acetate in 
o-xylene at 140 °C in nitrogen atmosphere 
within 4 hours, 2,3-bis(2-thienyl)chromone 24 
was obtained [9] (Scheme 7). 
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Scheme 7. The synthesis of 2,3-bis(2-thienyl)chromone 
 
The isomeric thienyl derivatives of chromone 
25 and 26 were obtained by the annulation 
reaction of salicylic aldehyde 22 with 
disubstituted alkyne 27 using the newly 
developed Ru(II) catalyst system in tert-amyl 
alcohol at 80 °C in air within 12 hours and were 
separated by column chromatography on silica 
gel [10] (Scheme 8). 
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Scheme 8. The synthesis of 2-aryl-3-(3- 
thienyl)chromone 
 
2. Synthesis of 3-thienyl/benzothienyl 
chromones by introduction of an S-
containing heterocycle to the chromone 
system 
       The classic way to obtain derivatives of 3-
hetarylchromones is the reaction of the 
interaction of 3-halochromone with derivatives 
of heteroarylboronic acid using a palladium 
catalyst.  
       The synthesis of the thienyl analogue of 
isoflavone 15 by the cross-coupling reaction of 
3-iodochromone 28 with thiophenboronic acid 
29 using tetrakis(triphenylphosphine)  
palladium as a catalyst in an argon atmosphere 
at room temperature was described in [11] 
(Scheme 9). 
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Scheme 9. The synthesis of 3-(2-thienyl)chromone 
Using the Suzuki coupling reaction of 3-
halogenflavones 30 and 31 with 
heteroarylboronic acids 32 and 33 made it 
possible to obtain 2-aryl-3-(2-
benzothienyl)chromone 34 and 2-aryl-3-(2-
thienyl)chromone 35 with pharmacophore 
groups [12 ] (Scheme 10). 
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 Scheme 10. The synthesis of 2-aryl-3(2- 
thienyl/benzothienyl)chromones with pharmacophore 
groups   
 
Сlaimed in the patent [13] 2-methyl-5,6,7-
trihydroxy-8-isobutyl-3-(2-
benzothienyl)сhromone 36 was also obtained by 
the Suzuki reaction from a derivative of 3-
iodochromone 37 and benzothiophenboronic 
acid 32 when using the Pd(dpf)2Cl2-CH2Cl2 
catalyst system and subsequent demethylation 
(Scheme 11). 
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Scheme 11. The synthesis of 2-methyl-5,6,7-trihydroxy-
8-isobutyl-3-(2-benzothienyl)chromone 
 
According to the Stille reaction, as a variant of 
the cross-coupling reaction, the interaction of 
(un)substituted 3-iodochromone and 
tetratiophenstannins in the presence of 
palladium on charcoal under mild conditions 
yielded (un)substituted derivatives of 3-(2-
thienyl)- and 3-(3-thienyl)chromones 38 [14] 
(Scheme 12). 
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Scheme 12. The synthesis of 3-(2-thienyl)- and 3-(3-
thienyl)chromones 
 
In the direct coupling reaction of 3-
bromochromone 39 with (un)substituted 
thiophene 40 and 3-methylbenzothiophene 41 
catalyzed by palladium, (un)substituted 3-(2-
thienyl)chromones 42 and 3-[2-(3-
methylbenzothienyl)]chromone 43 were 
obtained [15] (Scheme 13).  
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Scheme 13. The synthesis of (un)substituted 3-(2-
thienyl)chromones and 3-[2-(3-
methylbenzothienyl)]chromone 
 
The synthesis of 3-(2-thienyl)chromones 44a-c 
by direct coupling of (un)substituted 3-
iodochromone with thiophene under the 
conditions of the photochemical reaction in 
acetonitrile under a high-pressure mercury lamp 
without any catalysts and bases was proposed in 
the works [16, 17] (Scheme 14). 
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Scheme 14. The synthesis of 3-(2-thienyl)chromones 
 
3. Chemical properties of 3-
hetarylchromones with S-containing 
heterocycles 
 
Chemical properties are represented by a 
single example of the interaction of 3-(2-
thienyl)chromones 44a,b with hydrazine 
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hydrate [17]. The reaction was carried out at a 
ratio of the reagents chromone : hydrazine 
hydrate 1:2 in boiling alcohol to obtain 3-aryl-4-
(2-thienyl)-1H-pyrazoles 45a, b (Scheme 15).  
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Scheme 15. The synthesis of 3-aryl-4-(2-thienyl)-1H-
pyrazoles 
 
4. The biological activity of 3-
thienyl/benzothienylchromones and their 
transformation products 
 
When searching for drugs with a higher 
therapeutic index and less toxic side effects, 
considerable attention has been paid to 
compounds of the thiophene series, which have 
a wide spectrum of biological effects, namely, 
analgesic, antimicrobial, antihistamine, 
antispasmodic, anticonvulsant, antiviral, 
anticancer, diuretic, pesticidal and others [18]. 
       Recently, there have been many patent 
publications in which compounds of the 
thiophene and benzothiophene series are 
claimed to be selective modulators of estrogen 
receptors. 
       As for the thiophene analogues of 
isoflavones, according to the patents [19, 20], 
5,7-dihydroxy-3-(2-thienyl)chromone (3) and 
5,7-dihydroxy-3-(3-thienyl)chromone are ER-ß 
selective ligands having better selectivity 
compared to estrogen relative to estrogen-ß 
receptor compared to estrogen-α receptor and 
can be used in the treatment of diseases 
associated with the estrogen receptor-ß, in 
particular, Alzheimer's disease, anxious 
disorders, depressive disorders, osteoporosis, 
cardiovascular disease, rheumatoid arthritis or 
prostate cancer. It should be noted that in an 
early review, the absence of estrogenic activity 
of 5,7-dihydroxy-3-(2-thienyl)chromon was 
reported [21]. 
In the extended patent family [4, 22] 5- 
(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-
chromen-3-yl)thiophene-2-carboxylic acid (5) 
(IC50 < 0.1 μM ) and 5-(7-hydroxy-4-oxo-2- 
(trifluoromethyl)-4H-chromen-3-yl)thiophene-
3-carboxylic acid (6) (IC50 <1 μM) are claimed 
to be inhibitors of S-nitrosoglutathione 
reductase and may be used in the treatment of 
diseases and pathological conditions associated 
with impaired NO balance, such as pulmonary 
hypertension, ARDS, asthma, pneumonia, 
pulmonary fibrosis, cystic fibrosis, chronic 
obstructive pulmonary disease (COPD), 
hypertension, ischemic radar syndromes, 
gastrointestinal disorders, inflammatory 
diseases, degenerative neurological disorders. 
Current knowledge of the antiapoptotic 
Bcl-2 family role in cancer cells determine the 
targeting of this subfamily of proteins for 
therapeutic intervention in hyperproliferative 
diseases and malignant tumors. According to 
patent [13] in one embodiment 2-methyl-5,6,7-
trihydroxy-8-isobutyl-3-(2-
benzothienyl)chromone (36) is declared as 
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compound that is an inhibitor of the anti-
apoptotic family Bcl-2 and enhances cell 
sensitivity to apoptosis inducers, such as 
chemotherapy and radiation therapy, in animals. 
To solve the problem of overcoming the 
multidrug resistance of tumor cells a series of 
asymmetric and symmetric benzodipyranones 
was tested in vitro as P-glycoprotein inhibitors 
[5] (Figure 1). 
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Figure 1. General formula of asymmetric and symmetric  
benzodipyranones  
 
The test results revealed the structure-activity 
relationship of a series of P-gp inhibitors and 
compound-leader. The symmetric 
benzodipyranones proved to be inactive. 
Asymmetric benzodipyranones with electron-
donating substituents proved to be the most 
active (leader compound R = 3-methylphenyl), 
inhibition of P-gp activity was observed in 
compounds with electron-withdrawing 
substituents, compounds having thiophen-2-yl 
substituents (compound 11), 1-naphthyl, phenyl, 
cyclopropyl lost activity. 
Currently, topical search for new classes 
of biologically active compounds COX-2 
inhibitors, which are analogues coxibs in 
structure and action. Celecoxib (4-[5-(4-
methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl] 
benzenesulfonamide) and rofecoxib (4-(4-
methylsulfonylphenyl)-3-phenyl-5H-furan-2-
one) have sufficiently high clinical efficacy 
comparable to the therapeutic (anti-
inflammatory and analgesic) effect of traditional 
NSAIDs, however, due to the high specificity of 
the inhibitory effect on COX-2 and the absence 
of influence on the COX-1 isoenzyme 
(responsible for the development of side effects 
when using NSAIDs) they have low 
gastrointestinal toxicity and lack of effect on 
platelet activity. Flavone derivatives with the 
necessary pharmacophore groups and 
(hetero)aryl substituents at the 3-rd position 3 of 
the benzopyrone backbone, which can 
conditionally be considered as coxib analogues 
in structure, were tested for the inhibitory effect 
on COX-2 [12]. The results of testing of 
compounds of this series made it possible to 
draw certain conclusions about the structure-
activity relationship, and although some of the 
compounds (for example, compounds with a 
thienyl substituent 35 and a benzothienyl 
substituent 34) are practically inactive, and the 
highest activity was shown by the studied 2,3-
diarylchromones, although with significantly 
lower activity compared to coxibs, the search 
for COX-2 inhibitors among this class of 
compounds has a future. 
Tests of 3-(2-thienyl)chromonе 44 
transformation products under the action of a 
nucleophilic reagent - pyrazole compounds 45 
in vitro, on antifungal activity against five 
phytopathogenic fungi (Cytospora sp., 
Colletotrichum gloeosporioides, Botrytis 
cinerea, Alternaria solani and Fusarium solani) 
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showed that compounds 45a,b exhibit higher 
antifungal activity than the positive control of 
gimexazole against Cytospora sp., 
Colletotrichum gloeosporioides, Alternaria 
solani and Fusarium solani, however, they were 
almost inactive against Botrytis cinerea. The 
studied 3-aryl-4-(2-thienyl)-1H-pyrazoles 45a,b 
selectively inhibit the growth of Cytospora sp., 
Colletotrichum gloeosporioides. Thus, the 
growth inhibition rate of Colletotrichum 
gloeosporioides with an IC50 value of 12.86 
μg/ml of pyrazole 45a is much higher than the 
positive control of gimexazole (IC50 > 100 
μg/ml). 
 
Conclusions 
 
The considered methods for the 
synthesis of 3-thienyl/benzothienylchromones 
are quite simple and effective. The target 
products are mainly obtained with good and 
sometimes quite high yields. The directed 
functionalization of 3-hetarylchromones by 
introducing pharmacophore groups, such as 
CF3-, SO2CH3-, SO2NH2-, etc., as well as 
transforming into other heterocyclic systems, 
opens up wide possibilities for obtaining new 
substances, the spectrum of biological activity 
of which is significantly expanded and modified 
while maintaining a low toxicity level. 
Due to the great importance of benzopyrones 
and thiophene in nature, medical chemistry and 
chemistry of materials, one hopes that the 
appearance of practically significant derivatives 
of 3-hetarylchromones with S-containing 
heterocycles is only a matter of time.  
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